Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Resmetirom · Rezdiffra, MGL-3196

Small molecule · Agonist of thyroid hormone receptor-beta (THRB) · developed by Madrigal

Approved FDA, Mar 2024
MDGL Developer
6 Registered trials

What is Resmetirom?

Resmetirom is an oral thyroid hormone receptor-beta (THR-beta) agonist. It is studied in noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, and in heterozygous familial hypercholesterolemia and renal impairment.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rezdiffra, MGL-3196, VIA-3196
Drug type
Small molecule
Targets
thyroid hormone receptor-beta (THRB)
Mechanism
Agonist of thyroid hormone receptor-beta (THRB)
Therapy area
Gastroenterology
Developer
Madrigal (MDGL)
FDA status
Approved as Rezdiffra (March 14, 2024), NDA217785 · FDA label
UNII
RE0V0T1ES0

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07848191 Phase 4 MASH - Metabolic Dysfunction-Associated Steatohepatitis Recruiting MDGL
NCT03900429 Phase 3 NASH - Nonalcoholic Steatohepatitis Active not recruiting MDGL
NCT03038022 Phase 2 Heterozygous Familial Hypercholesterolemia Completed MDGL
NCT06397872 Phase 1 Renal Impairment Completed MDGL
NCT03413124 Phase 1 Healthy Completed MDGL
NCT01367873 Phase 1 Drug Safety Completed MDGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic SteatohepatitisDrug SafetyHealthyHeterozygous Familial HypercholesterolemiaRenal Impairment

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MDGL page.

Follow MDGL, the company behind Resmetirom

See MDGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MDGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.